A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas Newton, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT01651364
First received: February 20, 2012
Last updated: July 25, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to determine the effects of treatment with cabergoline, compared to treatment with placebo, on cocaine induced craving and subjective effects in cocaine-dependent human volunteers.


Condition Intervention Phase
Cocaine Dependence
Cocaine Abuse
Cocaine Addiction
Substance Abuse
Drug: Placebo
Drug: Cabergoline
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • The effects of treatment with cabergoline and cocaine on cardiovascular measures [ Designated as safety issue: Yes ]
    Before and after each cocaine infusion, physiologic responses will be closely monitored using repeated HR, BP, and ECG readings. To evaluate safety, a DSMB will meet annually and following any serious AE to examine data as well as any new published information on cabergoline relevant to the project. The number of AEs (including arrhythmias and ECG changes), changes in BP and HR, and changes in mood and psychiatric symptoms (using the BSI, BDI, POMS, and BPRS) will also be assessed throughout the study.


Secondary Outcome Measures:
  • The effects of treatment with cabergoline and cocaine on cocaine-induced craving and subjective effects [ Designated as safety issue: No ]
    The ability of cabergoline, as compared to placebo, to reduce cocaine-induced craving and to reduce reinforcing effects produced by cocaine will be measured by: 1. VAS, Adjective Scales, and MCQ; 2. Choices for cocaine vs. money in the self-administration assay.


Enrollment: 11
Study Start Date: July 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
Other Name: Sugar pill
Active Comparator: Cabergoline Drug: Cabergoline
Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
Other Names:
  • Dostinex
  • Cabaser

Detailed Description:

Secondary aims are to clarify the genetics of substance abuse, potentially leading to improved methods to diagnosis those at risk and to help develop better therapeutic interventions and to develop a new saliva-based test for the detection and measurement of drugs of abuse. As an additional aim, we will also collect blood samples for analyzing a number of genetic polymorphisms.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be English-speaking volunteers who are not seeking treatment at the time of the study.
  • Be between 18-55 years of age.
  • Meet DSM-IV TR criteria for cocaine dependence; participants may or may not meet criteria for nicotine dependence. Nicotine dependence is allowed but not required because most cocaine users smoke cigarettes.
  • Have a self-reported history of using cocaine by the smoked or IV route.
  • Have vital signs as follows: supine blood pressure > 100/65 mm Hg. To ensure that subjects will not be at risk from cocaine, the resting pulse must be < 90 bpm and the blood pressure must be < 150 mmHg systolic and < 90 mmHg diastolic.
  • Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) ≤ 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) within normal limits.
  • Have a baseline EKG that demonstrates clinically normal sinus rhythm, clinically normal conduction, and no clinically significant arrhythmias.
  • Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician and the principal investigator.
  • Females must have a negative urine pregnancy test during screening and at followup, on day 22.
  • Provide a negative urine test for cocaine metabolite on Day 1.

Exclusion Criteria:

  • Meet DSM IV TR criteria for dependence on drugs other than cocaine or nicotine.
  • Have any history or evidence suggestive of seizure disorder or brain injury.
  • Have any previous medically adverse reaction to cocaine, including loss of consciousness, chest pain, or epileptic seizure.
  • Have a history of heart valve disease.
  • Have any evidence from physical exam of heart murmur.
  • Have neurological or psychiatric disorders, such as: psychosis, bipolar illness or major depression as assessed by MINI; organic brain disease or dementia assessed by clinical interview; history of any psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past year and/or current suicidal ideation/plan.
  • Have evidence of clinically significant heart disease or hypertension, as determined by the PI.
  • Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease.
  • Have symptomatic HIV or are taking antiretroviral medication.
  • Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, upon hospital admission, and at the end of study participation.
  • Have asthma or currently use theophylline or other sympathomimetics.
  • Have any other illness, condition, or use of psychotropic medications, which in the opinion of the PI and/or the admitting physician would preclude safe and/or successful completion of the study.

Criteria for Discontinuation Following Initiation:

  • Inability to comply with study procedures.
  • Meet discontinuation criteria due to exaggerated response to cocaine, described below.
  • Use cocaine prior to randomization.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01651364

Locations
United States, Texas
Michael E. DeBakey VA Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
  More Information

No publications provided

Responsible Party: Thomas Newton, Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT01651364     History of Changes
Other Study ID Numbers: H-27036, DPMC, 2630090202
Study First Received: February 20, 2012
Last Updated: July 25, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Baylor College of Medicine:
Cocaine
Cabergoline

Additional relevant MeSH terms:
Cocaine-Related Disorders
Behavior, Addictive
Substance-Related Disorders
Mental Disorders
Compulsive Behavior
Impulsive Behavior
Cocaine
Cabergoline
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Antineoplastic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists

ClinicalTrials.gov processed this record on April 14, 2014